That’s the potential promise of a new study on a drug made by Japanese pharmaceutical company Shionogi. At a scientific ...

LONDON - Shionogi & Co., Ltd. (TYO:4507) has reported positive outcomes from its Phase 2a human challenge trial for an investigational oral antiviral candidate targeting Respiratory Syncytial ...

Shionogi has expanded its partnership with its Alzheimer’s drug development partner Tetra Therapeutics, giving an option for a buyout of the US biotech ahead of a key trial milestone.

The lack of available medications in the United States for COVID post-exposure prophylaxis leaves household members in close ...

While most pharma companies have exited the antibiotics area, Japanese drugmaker Shionogi has stuck with it and has just expanded its pipeline with a deal to buy US biotech Qpex Biopharma.

OSAKA, Japan & SACRAMENTO, Calif.--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, PhD.; hereinafter “Shionogi ...

Japan’s Shionogi (TYO: 4507) yesterday delivered a late-breaking scientific oral presentation at the Conference of ...

The oral drug Xocova marks the first home-grown medication, developed by Shionogi & Co., which can be prescribed for patients with mild symptoms, suggesting a stable supply of the tablet will be ...

Founded in 1878 and based in Osaka, Japan, Shionogi is a drug-discovery-based pharmaceutical company with more than 5,500 employees and operations around the globe, including offices in the US ...

Shionogi Inc., 300 Campus Drive, Florham Park, NJ 07932 USA Antimicrobial resistance (AMR) has become a serious threat to the effective prevention and treatment of infections caused by bacteria ...

1 Day SGIOY -2.62% DJIA 1.39% S&P 500 1.59% Health Care/Life Sciences -0.37% ...